March 22 (Reuters) - The U.S. Food and Drug
Administration (FDA) said on Friday it had granted traditional
approval for AbbVie's ( ABBV ) "guided missile" cancer therapy,
Elahere, for adult patients with a type of ovarian and related
cancers who have received one to three prior lines of treatment.